Shim Jae Hoon, Larson Gary, Wu Jim Zhen, Hong Zhi
Drug Discovery, ICN Pharmaceuticals, Costa Mesa, California 92626, USA.
J Virol. 2002 Jul;76(14):7030-9. doi: 10.1128/jvi.76.14.7030-7039.2002.
De novo RNA synthesis by hepatitis C virus (HCV) nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase has been investigated using short RNA templates. Various templates including those derived from the HCV genome were evaluated by examining the early steps of de novo RNA synthesis. NS5B was shown to be able to produce an initiation dinucleotide product from templates as short as 4-mer and from the 3'-terminal sequences of both plus and minus strands of the HCV RNA genome. GMP, GDP, and guanosine were able to act as an initiating nucleotide in de novo RNA synthesis, indicating that the triphosphate moiety is not absolutely required by an initiating nucleotide. Significant amounts of the initiation product accumulated in de novo synthesis, and elongation from the dinucleotide was observed when large amounts of dinucleotide were available. This result suggests that NS5B, a template, and incoming nucleotides are able to form an initiation complex that aborts frequently by releasing the dinucleotide product before transition to an elongation complex. The transition is rate limiting. Furthermore, we discovered that the secondary structure of a template was not essential for de novo initiation and that 3'-terminal bases of a template conferred specificity in selection of an initiation site. Initiation can occur at the +1, +2, or +3 position numbered from the 3' end of a template depending on base composition. Pyrimidine bases at any of the three positions are able to serve as an initiation site, while purine bases at the +2 and +3 positions do not support initiation. This result implies that HCV possesses an intrinsic ability to ensure that de novo synthesis is initiated from the +1 position and to maintain the integrity of the 3' end of its genome. This assay system should be an important tool for investigating the detailed mechanism of de novo initiation by HCV NS5B as well as other viral RNA polymerases.
利用短RNA模板对丙型肝炎病毒(HCV)非结构蛋白5B(NS5B)依赖RNA的RNA聚合酶进行的从头RNA合成研究。通过检查从头RNA合成的早期步骤,评估了包括源自HCV基因组的各种模板。结果表明,NS5B能够从短至4聚体的模板以及HCV RNA基因组正负链的3'-末端序列产生起始二核苷酸产物。GMP、GDP和鸟苷能够在从头RNA合成中作为起始核苷酸,这表明起始核苷酸并非绝对需要三磷酸基团。在从头合成中积累了大量的起始产物,并且当有大量二核苷酸时,观察到从二核苷酸开始的延伸。该结果表明,NS5B、模板和进入的核苷酸能够形成一个起始复合物,该复合物在转变为延伸复合物之前经常通过释放二核苷酸产物而终止。这种转变是限速的。此外,我们发现模板的二级结构对于从头起始并非必需,并且模板的3'-末端碱基在起始位点的选择上赋予了特异性。根据碱基组成,起始可以发生在从模板3'端编号的+1、+2或+3位置。这三个位置中任何一个位置的嘧啶碱基都能够作为起始位点,而+2和+3位置的嘌呤碱基不支持起始。该结果意味着HCV具有确保从头合成从+1位置起始并维持其基因组3'端完整性的内在能力。该检测系统应该是研究HCV NS5B以及其他病毒RNA聚合酶从头起始详细机制的重要工具。